(Q37854494)

24 August 2017

title

Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis (English)

1 reference

24 August 2017

Claudia Lebedinsky

1

1 reference

24 August 2017

Javier Gómez

2

1 reference

24 August 2017

Youn C Park

3

1 reference

24 August 2017

Antonio Nieto

4

1 reference

24 August 2017

Arturo Soto-Matos

5

1 reference

24 August 2017

Trilok Parekh

6

1 reference

24 August 2017

Vicente Alfaro

7

1 reference

24 August 2017

Elena Roy

8

1 reference

24 August 2017

Pilar Lardelli

9

1 reference

24 August 2017

Carmen Kahatt

10

1 reference

24 August 2017

publication date

18 March 2011

1 reference

Cancer Chemotherapy and Pharmacology

24 August 2017

published in

1 reference

24 August 2017

volume

68

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

1223-1231

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

24 August 2017

1 reference

Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiovascular toxicity caused by cancer treatment: strategies for early detection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiac toxicity from systemic cancer therapy: a comprehensive review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Trabectedin : a review of its use in the management of soft tissue sarcoma and ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Relevance of the Fanconi anemia pathway in the response of human cells to trabectedin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Preclinical and clinical results with the natural marine product ET-743

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Trabectedin for women with ovarian carcinoma after treatment with platinum and taxanes fails.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

A phase II study of Yondelis (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiac dysfunction in the trastuzumab clinical trials experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiotoxicity associated with trastuzumab treatment of HER2+ breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sézary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Antineoplastic chemotherapy induced QTc prolongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

The cardiotoxic potential of the 5-HT(3) receptor antagonist antiemetics: is there cause for concern?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Detection and monitoring of cardiotoxicity-what does modern cardiology offer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

The diagnosis and management of cardiovascular disease in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Molecularly targeted oncology therapeutics and prolongation of the QT interval

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

Cardiotoxicity of Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00280-011-1614-Z

10.1007/S00280-011-1614-Z

21 January 2018

Identifiers

DOI

1 reference

24 August 2017

1 reference